American Journal of Obstetrics & Gynecology
Volume 188, Issue 6 , Pages 1556-1564 , June 2003

Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602)

Presented at the Sixty-Ninth Annual Meeting of the Pacific Coast Obstetrical and Gynecological Society, October 22-27, 2002, Rancho Mirage, Calif

References 

  1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;16:1070
  2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1999;49:8–31
  3. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definition of the treated population. J Clin Oncol. 1992;10:513–514
  4. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–393
  5. Lund B, Krisjansen PE, Hansen HH. Clinical and preclinical activity of 2′, 2′ diflurorodeoxy-cytidine (gemcitabine). Cancer Treat Rev. 1993;19:45–55
  6. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′, 2′ difurorodeoxy-cytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86:1530–1533
  7. Lund B, Hansen OP, Neijt JP, Thellade K, Hansen M. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs. 1995;6(6 Suppl):61–62
  8. Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, et al.  A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 1998;9:1265–1267
  9. Orlando M, Mandachain M. Gemcitabine in ovarian cancer. Semin Oncol. 2001;28(3 Suppl):62–69
  10. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol. 2002;29(1 Suppl):9–10
  11. Ozols RF. The current role of gemcitabine in ovarian cancer. Semin Oncol. 2001;28(2 Suppl):18–24
  12. Thigpen T, Vance R, Puneky L, Hanson R. Chemotherapy in advance ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol. 1994;55:S97–S107
  13. Ovarian Cancer Meta-analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol. 1995;13:726–732
  14. A’Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol. 1995;13:726–732
  15. Perez-Manga G, Lluch A, Alba JA, Moreno-Nogueira M, Palomero J, Garcia-Conde D, et al.  Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol. 2000;18:2545–2552
  16. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al.  The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579
  17. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7:361–364
  18. Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol. 1999;10(1 Suppl):21–27
  19. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al.  Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14:1545–1551
  20. Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853–855
  21. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, et al.  Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996;63:89–93
  22. Silver DF, Piver MS. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol. 1999;22:450–452
  23. Coenen M, Berteloot P, Amant F, Vangramberen M, Vergote I. Gemcitabine in platin-paclitaxel resistant ovarian carcinoma. [abstract] Proc Am Soc Clin Oncol. 2000;19:405a
  24. Kudelka AP, Verschraegen CF, Edwards CL, Freedman RS, Plunket WK, Nicol S, et al.  A preliminary report of a phase 2 study of gemcitabine in women with refractory mullerian (ovarian, fallopian tube and primary peritoneal) carcinomas. [abstract] Proc Am Soc Clin Oncol. 1999;18:377a
  25. Du Bois A, Luck HJ, Pfisterer J, Schroeder W, Blohmer JU, Kimmig R, et al.  Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer—a dose-finding study by the arbeitgemeinschaft gynakologische onkologie (AGO) ovarian cancer study group. Ann Oncol. 2001;12:1115–1120
  26. D’Agostino G, Ferrandina G, Garganese G, Salerno MG, Lorussso D, Farnetano MG, et al.  Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology. 2002;62:110–114
  27. Pignata S, Varriale E, Casella G, Iodice F, De Placido G, Perrone F, et al.  A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. Ann Oncol. 2000;11:613–616
  28. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286–291

☆ Supported in part by Lilly Oncology and the Fred Hutchinson Cancer Research Center.c

☆☆ Reprint requests: Barbara A. Goff, MD, Department of Obstetrics and Gynecology, Box 356460, University of Washington School of Medicine, Seattle, WA 98l95-6460.

PII: S0002-9378(03)00352-1

doi: 10.1067/mob.2003.398

American Journal of Obstetrics & Gynecology
Volume 188, Issue 6 , Pages 1556-1564 , June 2003

Article Tools

* Image Usage & Resolution